Magnetic resonance-guided focused ultrasound (MRgFUS) is a non-invasive technique for neuroregulation

The mechanism of MRI-guided focused ultrasound. Graphic courtesy of Haoxuan Lu, Yujue Zhong, et al.


April 8, 2024 — Magnetic resonance-guided focused ultrasound (MRgFUS) is a non-invasive technique for neuroregulation. It offers several advantages, including being non-invasive, eliminates the need for general anesthesia requirement, and enables real-time target localization and real-time temperature monitoring. Currently, the U.S. Food and Drug Administration has approved this technology for the treatment of essential tremor and Parkinson's disease, and its indications are expanding to include various intracranial diseases.

In a new review published in the KeAi journal Meta-Radiology, a team of researchers from the Chinese PLA General Hospital in China summarized the clinical trials of high-intensity FUS in the treatment of intracranial diseases. The team searched the PubMed, Embase, and Web of Science databases from January 1, 2013, to November 1, 2023, using the search terms: “MRgFUS,” or “MRI-guided Focused Ultrasound,” or “magnetic resonance imaging-guided focused ultrasound,” or “magnetic resonance-guided focused ultrasound.”

“According to the inclusion and exclusion criteria for initial literature screening, we identified several current intracranial applications of magnetic resonance-guided high-intensity focused ultrasound, which include “essential tremor,” "Parkinson's disease,” “obsessive compulsive disorder,” “major depressive disorder,” “neuropathic pain,” and “focal dystonia”,” shares corresponding author Xin Lou.

The review also introduces the preclinical and clinical studies on low-intensity FUS-induced blood-brain barrier opening and neuromodulation, and discusses the challenges and future directions of MRgFUS technology.

“We found that MRgFUS has emerged as a novel therapeutic approach in functional neurosurgery. High-intensity FUS is a safe and effective treatment for various intracranial diseases. Nonetheless, the neurobiological effects of low intensity FUS- blood–brain barrier opening and neuromodulation are not fully understood. Therefore, further preclinical and clinical studies are required to explore these effects. Neuroimaging is essential for localizing targets and exploring potential neurobiological effects in MRgFUS,” concludes Lou.

For more information: https://www.keaipublishing.com/


Related Content

News | Artificial Intelligence

April 16, 2025 — An artificial intelligence (AI) program trained to review images from a common medical test can detect ...

Time April 16, 2025
arrow
News | Ultrasound Women's Health

April 11, 2025 — Contrast-enhanced ultrasound (CEUS) is a safe and accurate diagnostic imaging option for pregnant women ...

Time April 11, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Focused Ultrasound Therapy

March 31, 2025 — Neuropathic pain affects up to 10 percent of the global population and can be challenging to manage ...

Time April 02, 2025
arrow
News | Breast Imaging

March 20, 2025 — GE HealthCare has launched Invenia Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound ...

Time March 21, 2025
arrow
News | X-Ray

March 18, 2025 — GE HealthCare recently announced a collaboration with NVIDIA expanding the existing relationship ...

Time March 19, 2025
arrow
News | Breast Imaging

Feb. 26, 2025 — iCAD, Inc. a provider of clinically proven AI-powered cancer detection solutions, and Koios Medical, a ...

Time March 03, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Focused Ultrasound Therapy

Jan. 8, 2025 - EDAP TMS SA, a supplier of robotic energy-based therapies, has announced that the first patient has been ...

Time January 08, 2025
arrow
Subscribe Now